Cancer Biomarkers Market to Grow at 18.26% CAGR to 2019: Focus on USA

PUNE, India, November 27, 2015 /PRNewswire/ --

Growing popularity of companion diagnostics is one of the major trends emerging in cancer biomarkers market with pharmaceutical companies and diagnostic manufacturers working together to develop in-demand companion diagnostic tests.

Complete report on global cancer biomarkers market spread across 89 pages, profiling 6 major companies and providing 29 data exhibit is now available at http://www.rnrmarketresearch.com/global-cancer-biomarkers-market-2015-2019-market-report.html.

The analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26% over the period 2014-2019. According to the report, the increased prevalence of cancer is one of the key drivers in this market. Globally, the prevalence of cancer is growing at a significant pace. According to researchers, a sedentary lifestyle, poor diet, smoking, and alcohol are among the key external factors contributing to the rise in new cancer cases each year. Some of the internal factors that contribute to the incidence of cancer include inherited mutations, hormonal imbalance, and mutations that occur from metabolism.

Further, the Global Cancer Biomarkers Market 2015-2019 report states that one of the key challenges in the market is the poor regulatory and reimbursement systems. In most countries, regulatory and reimbursement procedures are not ideal to deal with molecular biomarker-based diagnostic tests. Poorly adapted regulatory and reimbursement systems act as a barrier to the inclusion of biomarker-based diagnostic tests in the clinical setting and may further hinder drug development.

The report recognizes the following companies as the key players in the Global Cancer Biomarkers Market: Abbott Laboratories, Affymetrix Inc., Illumina Inc., Qiagen NV, Quest Diagnostics and Roche Diagnostics. Order a Copy of Global Cancer Biomarkers Market 2015 - 2019 report at http://www.rnrmarketresearch.com/contacts/purchase?rname=263966.

Other Prominent Vendors in the market are Agendia, Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US, Astex Pharmaceuticals, Atossa Genetics, Beckman Coulter, Becton, Dickinson and Co., Biocurex, bioMérieux, Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma, Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron, Immunomedics, Morphotek, Myriad Genetics, Nodality, Northwest Biotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers and Vermillion.

Another related report is Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis). This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Access complete report at http://www.rnrmarketresearch.com/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipelin-market-report.html.

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
[email protected]

SOURCE RnR Market Research